AstraZeneca's Lynparza gets EMA panel nod for expanded use in breast cancer subtype

Retrieved on: 2022-06-24 13:50:22

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca's Lynparza gets EMA panel nod for expanded use in breast cancer subtype. View article details on hiswai:

Excerpt

A panel of the European Medicines Agency ((EMA)) recommended the expanded approval of AstraZeneca's blockbuster cancer drug Lynparza.

Article found on: seekingalpha.com